Galapagos, MorphoSys Add One More Antibody To Alliance

The alliance aims to discover and develop antibody therapeutics based on novel modes of action in bone and joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis. As part of the initial agreement, three targets were selected for the collaboration.

Galapagos and MorphoSys said that the antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific in-vitro and in-vivo experiments. In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development.

Reportedly, based on this, Galapagos and MorphoSys have now added a fourth antibody target to the alliance. The partners have prioritised the targets in order to maximise the value and IP position of the respective therapeutic antibody programs.

Onno van de Stolpe, CEO of Galapagos, said: “This collaboration provides Galapagos with a platform to develop antibody drugs for our proprietary targets. This, together with more than 40 R&D small molecule programs, solidifies our leading position in discovering innovative approaches to address diseases with unmet medical need.”

Marlies Sproll, chief scientific officer of MorphoSys, said: “The expansion of our proprietary pipeline is a key value driver for our company. In 2010, we plan to add up to four new proprietary programs including both fully owned and co-development opportunities such as with Galapagos. Our alliance with Galapagos gives us access to novel disease-related target molecules which could build the basis for first-in-class antibody therapies in the future.”